Citadel Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.04M | Sell |
145,493
-164,582
| -53% | -$2.31M | ﹤0.01% | 2669 |
|
|
2025
Q1 | $4.85M | Buy |
310,075
+220,907
| +248% | +$3.45M | ﹤0.01% | 1787 |
|
|
2024
Q4 | $1.24M | Sell |
89,168
-2,941,905
| -97% | -$41M | ﹤0.01% | 3064 |
|
|
2024
Q3 | $28.2M | Buy |
3,031,073
+98,426
| +3% | +$915K | 0.01% | 706 |
|
|
2024
Q2 | $27.3M | Buy |
2,932,647
+1,018,377
| +53% | +$9.47M | 0.01% | 732 |
|
|
2024
Q1 | $19M | Buy |
+1,914,270
| New | +$19M | ﹤0.01% | 911 |
|
|
2023
Q4 | – | Sell |
-250,535
| Closed | -$1.33M | – | 5872 |
|
|
2023
Q3 | $1.33M | Buy |
250,535
+196,127
| +360% | +$1.04M | ﹤0.01% | 2772 |
|
|
2023
Q2 | $519K | Sell |
54,408
-217,113
| -80% | -$2.07M | ﹤0.01% | 3605 |
|
|
2023
Q1 | $2.99M | Buy |
271,521
+261,888
| +2,719% | +$2.88M | ﹤0.01% | 2185 |
|
|
2022
Q4 | $143K | Sell |
9,633
-70,882
| -88% | -$1.05M | ﹤0.01% | 4856 |
|
|
2022
Q3 | $1.54M | Sell |
80,515
-111,996
| -58% | -$2.14M | ﹤0.01% | 2997 |
|
|
2022
Q2 | $4.1M | Buy |
192,511
+15,811
| +9% | +$337K | ﹤0.01% | 2048 |
|
|
2022
Q1 | $3.4M | Sell |
176,700
-70,215
| -28% | -$1.35M | ﹤0.01% | 2427 |
|
|
2021
Q4 | $5.12M | Sell |
246,915
-19,017
| -7% | -$394K | ﹤0.01% | 2079 |
|
|
2021
Q3 | $6.35M | Sell |
265,932
-175,580
| -40% | -$4.19M | ﹤0.01% | 1843 |
|
|
2021
Q2 | $12M | Sell |
441,512
-10,944
| -2% | -$299K | ﹤0.01% | 1304 |
|
|
2021
Q1 | $13.1M | Buy |
452,456
+318,753
| +238% | +$9.22M | ﹤0.01% | 1238 |
|
|
2020
Q4 | $3.76M | Buy |
133,703
+118,353
| +771% | +$3.33M | ﹤0.01% | 2005 |
|
|
2020
Q3 | $450K | Sell |
15,350
-17,739
| -54% | -$520K | ﹤0.01% | 3582 |
|
|
2020
Q2 | $1M | Sell |
33,089
-22,476
| -40% | -$679K | ﹤0.01% | 2859 |
|
|
2020
Q1 | $1.66M | Buy |
+55,565
| New | +$1.66M | ﹤0.01% | 2402 |
|